Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
David Henry MD
David Henry MD Advisory Board
Eric Jonasch MD
Eric Jonasch MD Advisory Board
Elizabeth Smyth MD
Elizabeth Smyth MD Advisory Board
See All Experts
featured
Published in Oncology

Expert Opinion / Conference Coverage · June 17, 2015

ASCO 2015 Recap: The Case for Changing the Class of Systemic Agent for Disease Progression or Intolerance of First-Line Therapy—Part 3

Tony Nimeh MD
Written by
Tony Nimeh MD

 

 Save  Recommend
 Share

Additional Info

Further Reading

Most Read This Week

Recently Updated